MacDonald Kelly's Insider Trades & SAST Disclosures
MacDonald Kelly's most recent trade in Dynavax Technologies Corp. was a trade of 15,477 Restricted Stock Unit done . Disclosure was reported to the exchange on Feb. 18, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern MacDonald Kelly.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 15,477 | 30,953 | - | - | Restricted Stock Unit | |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 15,477 | 34,202 (0%) | 0% | - | Common Stock | |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.93 per share. | 18 Feb 2025 | 4,975 | 29,227 (0%) | 0% | 12.9 | 64,327 | Common Stock |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 42,424 | 42,424 | - | - | Restricted Stock Unit | |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 16,000 | 24,043 (0%) | 0% | - | Common Stock | |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 16,000 | 0 | - | - | Restricted Stock Unit | |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 16,000 | 16,000 | - | - | Restricted Stock Unit | |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.69 per share. | 13 Feb 2025 | 5,318 | 18,725 (0%) | 0% | 12.7 | 67,485 | Common Stock |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 5,333 | 10,040 (0%) | 0% | - | Common Stock | |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 5,333 | 0 | - | - | Restricted Stock Unit | |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.20 per share. | 10 Feb 2025 | 1,997 | 8,043 (0%) | 0% | 13.2 | 26,360 | Common Stock |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 65,000 | 65,000 | - | - | Stock Options (Right to Buy) | |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 46,430 | 46,430 | - | - | Restricted Stock Unit | |
| Dynavax Technologies Corp. | MacDonald Kelly | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2024 | 5,333 | 5,333 | - | - | Restricted Stock Unit | |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2024 | 5,333 | 7,692 (0%) | 0% | - | Common Stock | |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.82 per share. | 10 Feb 2024 | 2,985 | 4,707 (0%) | 0% | 12.8 | 38,268 | Common Stock |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 5,334 | 5,334 (0%) | 0% | - | Common Stock | |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 5,334 | 10,666 | - | - | Restricted Stock Unit | |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.36 per share. | 27 Feb 2023 | 2,975 | 2,359 (0%) | 0% | 10.4 | 30,821 | Common Stock |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 90,500 | 90,500 | - | - | Stock Option (Right to Buy) | |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 16,000 | 16,000 | - | - | Restricted Stock Unit | |
| Dynavax Technologies Corp. | Kelly MacDonald | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 350,000 | 350,000 | - | - | Stock Option (Right to Buy) | |
| Ironwood Pharmaceuticals I... | Kelly MacDonald | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.12 per share. | 04 Dec 2020 | 5,639 | 98,680 (0%) | 0% | 9.1 | 51,428 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Kelly MacDonald | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 12.50 per share. | 04 Dec 2020 | 5,639 | 93,041 (0%) | 0% | 12.5 | 70,488 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Kelly MacDonald | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2020 | 5,639 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Ironwood Pharmaceuticals I... | Kelly MacDonald | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2020 | 3,561 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Ironwood Pharmaceuticals I... | Kelly MacDonald | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 11.75 per share. | 11 Nov 2020 | 3,561 | 93,041 (0%) | 0% | 11.8 | 41,842 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Kelly MacDonald | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.31 per share. | 11 Nov 2020 | 3,561 | 96,602 (0%) | 0% | 9.3 | 33,153 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Kelly MacDonald | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 11.25 per share. | 06 Nov 2020 | 1,872 | 93,966 (0%) | 0% | 11.3 | 21,060 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Kelly MacDonald | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 10.92 per share. | 06 Nov 2020 | 825 | 93,141 (0%) | 0% | 10.9 | 9,009 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Kelly MacDonald | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 10.92 per share. | 06 Nov 2020 | 100 | 93,041 (0%) | 0% | 10.9 | 1,092 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Kelly MacDonald | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 10.50 per share. | 08 Oct 2020 | 22,714 | 95,838 (0%) | 0% | 10.5 | 238,497 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Kelly MacDonald | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 10.14 per share. | 17 Aug 2020 | 575 | 118,552 (0%) | 0% | 10.1 | 5,831 | Class A Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges